PD-L1

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman, Seth M. Steinberg, James L. Gulley

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 91; DOI: 10.1186/s40425-018-0409-8
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 46; DOI: 10.1186/s40425-018-0361-7
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model
Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski, Gabriel Helmlinger

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 17; DOI: 10.1186/s40425-018-0327-9
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, Tian Zhang

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 4; DOI: 10.1186/s40425-018-0314-1
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 7; DOI: 10.1186/s40425-017-0310-x
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky, Christian Grommes

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 99; DOI: 10.1186/s40425-017-0302-x
Biomarkers for immunotherapy in bladder cancer: a moving target
David H. Aggen, Charles G. Drake

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 94; DOI: 10.1186/s40425-017-0299-1
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal, David Jablons

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 75; DOI: 10.1186/s40425-017-0281-y
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
Quaovi Sodji, Kandy Klein, Kavuri Sravan, Jigarkumar Parikh

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 62; DOI: 10.1186/s40425-017-0267-9
Adoptive cell therapy using PD-1⁺ myeloma-reactive T cells eliminates established myeloma in mice
Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese, Bryon D. Johnson

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 51; DOI: 10.1186/s40425-017-0256-z

Main menu

PD-L1

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

PD-L1

Pages